Payment overview · 2025
General Payments
$5,595.01
198 reported records · 33 companies
Healthcare provider profile · identity verified
Alexander D Doan, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · SAN JOSE, CA · NPI 1003859661
Verified facts
What the public records show
CMS Open Payments records show Alexander D Doan, MD received $5,595.01 in general payments during 2025 across 198 reported records.
Novo Nordisk Inc accounted for 12.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Acthar, Eliquis, Farxiga, Jardiance, Kerendia, Korlym, Linzess, Lokelma, Ozempic, Prolia, Rayaldee, Rybelsus, Velphoro, Veltassa, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 344 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Korlym by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Nexlizet by this doctor in 2024.
Fresenius USA Marketing, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VELPHORO as an associated drug or biological on 8763 records involving 2642 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Velphoro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Mallinckrodt Hospital Products Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ACTHAR as an associated drug or biological on 35914 records involving 11592 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Acthar by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Wegovy by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Rayaldee by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
Travere Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Filspari as an associated drug or biological on 8542 records involving 2693 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Filspari by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $713.99 | 12.8% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $591.81 | 10.6% | 21 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $585.08 | 10.5% | 21 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $462.12 | 8.3% | 21 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $461.11 | 8.2% | 13 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $335.95 | 6.0% | 12 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $300.70 | 5.4% | 8 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $245.76 | 4.4% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $221.60 | 4.0% | 10 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $218.37 | 3.9% | 12 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $203.82 | 3.6% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $197.58 | 3.5% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $172.62 | 3.1% | 8 | 2025 |
| Vantive US Healthcare LLC | Unresolved — no canonical attribution shown | $143.25 | 2.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $127.10 | 2.3% | 5 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $81.79 | 1.5% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $59.28 | 1.1% | 2 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $54.75 | 1.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.21 | 0.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.90 | 0.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $43.62 | 0.8% | 2 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.11 | 0.6% | 2 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $30.93 | 0.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.98 | 0.5% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $27.85 | 0.5% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $24.89 | 0.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.37 | 0.4% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $21.17 | 0.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.87 | 0.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.20 | 0.4% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.66 | 0.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.28 | 0.3% | 1 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.29 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,540.26 | 195 |
| Education | $54.75 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $461.11 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $438.17 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $367.18 | 8 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $335.95 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $330.37 | 12 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $325.64 | 15 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $300.70 | 8 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $266.08 | 6 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $245.76 | 9 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $221.60 | 10 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $218.37 | 12 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $203.82 | 4 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $172.62 | 8 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $153.64 | 7 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $150.44 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $145.32 | 7 | 2025 |
Source payment records
|
|||||
| Renal - PD Normalized: renal pd |
Device | Vantive US Healthcare LLC | $143.25 | 1 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $141.35 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $136.48 | 6 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $127.10 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $115.66 | 6 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $81.79 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $69.27 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $59.28 | 2 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $56.23 | 2 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $54.75 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $49.21 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.90 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $43.62 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | MERZ NORTH AMERICA, INC. | $30.93 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.98 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $27.85 | 1 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| Empaveli Normalized: empaveli |
Drug | Apellis Pharmaceuticals, Inc. | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ACTHAR acthar |
2025 | Acthar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 56 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 234 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 344 | exact normalized | Medicare Part D |
| Korlym korlym |
2025 | Korlym | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 37 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 149 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 29 | exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 173 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 58 | exact normalized | Medicare Part D |
| VELPHORO velphoro |
2025 | Velphoro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 121 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | 14 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
29 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
234 | 59 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
344 | 81 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
| Fresenius USA Marketing, Inc. Exact reporting entity; no affiliate inference |
2025 | VELPHORO open payments reported associated product |
CMS Open Payments — General Payments 8763 supporting records · 2642 recipient NPIs · example record 1244803773 |
Velphoro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Mallinckrodt Hospital Products Inc. Exact reporting entity; no affiliate inference |
2025 | ACTHAR open payments reported associated product |
CMS Open Payments — General Payments 35914 supporting records · 11592 recipient NPIs · example record 1211945432 |
Acthar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
149 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
173 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Travere Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Filspari open payments reported associated product |
CMS Open Payments — General Payments 8542 supporting records · 2693 recipient NPIs · example record 1244395624 |
Filspari · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
121 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Kerendia | Finerenone | 344 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 292 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 259 | 86 |
| Furosemide | Furosemide | 240 | 90 |
| Farxiga | Dapagliflozin Propanediol | 234 | 59 |
| Valsartan | Valsartan | 210 | 72 |
| Rayaldee | Calcifediol | 173 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 53 |
| Losartan Potassium | Losartan Potassium | 158 | 60 |
| Ozempic | Semaglutide | 149 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 39 |
| Veltassa | Patiromer Calcium Sorbitex | 121 | 26 |
| Vascepa | Icosapent Ethyl | 120 | 38 |
| Metformin Hcl | Metformin Hcl | 118 | 37 |
| Calcitriol | Calcitriol | 101 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 95 | 27 |
| Tradjenta | Linagliptin | 93 | 25 |
| Allopurinol | Allopurinol | 89 | 30 |
| Lisinopril | Lisinopril | 89 | 26 |
| Procrit | Epoetin Alfa | 89 | 27 |
| Glipizide Er | Glipizide | 82 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 26 |
| Clonidine Hcl | Clonidine Hcl | 66 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 22 |
| Carvedilol | Carvedilol | 61 | 20 |
| Repatha Sureclick | Evolocumab | 61 | suppressed |
| Rybelsus | Semaglutide | 58 | 15 |
| Eliquis | Apixaban | 56 | 15 |
| Gabapentin | Gabapentin | 54 | 19 |
| Clinolipid | Fat Emulsion/Olive/Soy/Phospho | 51 | suppressed |
| Tolvaptan | Tolvaptan | 48 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 47 | 11 |
| Lorazepam | Lorazepam | 45 | suppressed |
| Finasteride | Finasteride | 44 | 14 |
| Famotidine | Famotidine | 43 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 41 | 17 |
| Filspari | Sparsentan | 38 | suppressed |
| Linzess | Linaclotide | 37 | 14 |
| Mirtazapine | Mirtazapine | 37 | 12 |
| Ezetimibe | Ezetimibe | 36 | 17 |
| Korlym | Mifepristone | 36 | suppressed |
| Prednisone | Prednisone | 36 | 18 |
| Spironolactone | Spironolactone | 36 | 16 |
| Icosapent Ethyl | Icosapent Ethyl | 35 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 33 | 16 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 30 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Prolia | Denosumab | 29 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 25 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 22 |
| Megestrol Acetate | Megestrol Acetate | 24 | suppressed |
| Omeprazole | Omeprazole | 24 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Calcium Acetate | Calcium Acetate | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Irbesartan | Irbesartan | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Tacrolimus | Tacrolimus | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 17 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Erythromycin | Erythromycin Base | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Wegovy | Semaglutide | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Acthar | Corticotropin | 12 | suppressed |
| Epogen | Epoetin Alfa | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 11 | suppressed |
| Prosol | Parenteral Amino Acid 20% No.1 | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,595.01 · 198 records | Novo Nordisk Inc | ACTHAR, BENLYSTA, CONTRAVE, CRYSVITA, Dexcom G6 Transmitter, ELIQUIS, EVENITY, Empaveli, FARXIGA, FUROSCIX, Fabhalta, GVOKE HYPOPEN, IBSRELA, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, LOKELMA, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PROLIA, PURIFIED CORTROPHIN GEL, RAYALDEE, REPATHA, Renal - PD, Rybelsus, TARPEYO, TAVNEOS, Tymlos, VELPHORO, VERQUVO, VOYXACT, Vafseo, Veltassa, Wegovy, Xeomin, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Acthar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error